Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alisertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 7/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 4/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | HCK | P08631 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | FER | P16591 | 2/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 2/20 | 1.00 |
| ▸ | GRK5 | P34947 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alisertib SCHEMBL29354333 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL855823 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL29437869 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL29750414 | 1.00 | AURKA (1.00) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL15263514 | 0.99 | AURKA (0.98) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL854553 | 0.99 | AURKA (0.98) | AURKAAURKBKDRGABRA1PLK4 | |
| Alisertib SCHEMBL14125416 | 0.98 | AURKA (0.97) | AURKAAURKBKDRGABRA1PLK4 | |
| SCHEMBL2389378 | 0.97 | AURKA (0.94) | AURKAAURKBKDRGABRA1PLK4 | |
| SCHEMBL2389355 | 0.94 | AURKA (0.89) | AURKAAURKBKDRGABRA1PLK4 | |
| SCHEMBL20214913 | 0.94 | AURKA (0.89) | AURKAAURKBKDRGABRA1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400567-A1 | AURORA KINASE INHIBITORS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARM INC (US) | 2024-12-05 | — | — | US | claimed |
| US-12042499-B2 | Administration of aurora kinase inhibitor and chemotherapeutic agents | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | claimed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025245045-A1 | METHODS OF TREATING LUNG CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-3429571-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | ORYZON GENOMICS SA (ES) | 2025-10-08 | — | — | EP | disclosed |
| EP-4568674-A1 | COMBINATION OF ANTICANCER AGENTS COMPRISING A BIFUNCTIONAL COMPOUND WITH G12D MUTANT KRAS INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025075211-A1 | ALISERTIB AND PACLITAXEL FOR TREATING SMALL CELL LUNG CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-04-10 | — | — | WO | disclosed |
| CN-119677517-A | Combination of anticancer agents comprising bifunctional compounds having G12D mutant KRAS inhibitory activity | 安斯泰来制药株式会社 | 2025-03-21 | — | — | CN | disclosed |
| US-20240400567-A1 | AURORA KINASE INHIBITORS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARM INC (US) | 2024-12-05 | — | — | US | disclosed |
| CN-119031912-A | BCL-2 inhibitors and aurora kinase inhibitors for the treatment of cancer | 基因组研究有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024033537-A1 | COMBINATION OF ANTICANCER AGENTS COMPRISING A BIFUNCTIONAL COMPOUND WITH G12D MUTANT KRAS INHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2024-02-15 | — | — | WO | disclosed |
| EP-4277706-A1 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023204800-A1 | COMBINATION THERAPY | US ONCOLOGY CORPORATE, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2022154664-A1 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400567-A1 | AURORA KINASE INHIBITORS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885KDR 2988/4885 |
| US-12042499-B2 | Administration of aurora kinase inhibitor and chemotherapeutic agents | AURKB, AURKA, AURKC | AURKA 2/4885AURKB 1/4885KDR 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.